Pharma C Investments Past Earnings Performance
Past criteria checks 0/6
Pharma C Investments's earnings have been declining at an average annual rate of -7.9%, while the Capital Markets industry saw earnings growing at 14.9% annually.
Key information
-7.9%
Earnings growth rate
13.1%
EPS growth rate
| Capital Markets Industry Growth | 16.3% |
| Revenue growth rate | n/a |
| Return on equity | -72.1% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Pharma C Investments makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | 0 | 0 | 0 |
| 31 Mar 23 | 0 | 0 | 0 | 0 |
| 31 Dec 22 | 0 | 0 | 0 | 0 |
| 30 Sep 22 | 0 | 0 | 0 | 0 |
| 30 Jun 22 | 0 | 0 | 0 | 0 |
| 31 Mar 22 | 0 | 0 | 0 | 0 |
| 31 Dec 21 | 0 | -1 | 0 | 0 |
| 30 Sep 21 | 0 | 0 | 0 | 0 |
| 30 Jun 21 | 0 | 0 | 0 | 0 |
| 31 Mar 21 | 0 | 0 | 0 | 0 |
| 31 Dec 20 | 0 | 0 | 0 | 0 |
Quality Earnings: MCAI is currently unprofitable.
Growing Profit Margin: MCAI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MCAI is unprofitable, and losses have increased over the past 5 years at a rate of 7.9% per year.
Accelerating Growth: Unable to compare MCAI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MCAI is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (-12.2%).
Return on Equity
High ROE: MCAI has a negative Return on Equity (-72.14%), as it is currently unprofitable.